According to VCBeat, on June 29, 2020, Denovo Biopharma, a leading precision medicine company, announced the completion of ¥590 million Series C financing, led by CICC Qide Innovative Biomedicine Fund, with additional support from existing shareholders including Jiuyo Capital, Share Capital, CITIC Securities and Sangel Capital, and new investors including Yingke PE, Guozhong Capital and Kaitou Hanrun Investment.
Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. Its platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.
Up to now, Denovo Biopharma has global rights of six first-in-class drugs (DB102 to DB107) that have been developed in the clinical stage for cancers and psychiatric diseases. DB102 (enzastaurin) is an anti-tumor drug that Lilly conducted many clinical studies within a variety of tumor indications. Then Denovo Biopharma acquired global rights to enzastaurin from Lilly and has completed the identification of the biomarker, which is significantly correlated with the expected therapeutic effects on DLBCL and GBM patients, and has filed international patent applications.
The clinical trials of DB102 in several countries for newly diagnosed GBM has also been approved by the FDA and China's NMPA and will be conducted this year.
About Jiuyo Capital
Founded by more than 100 partners with financial and industrial background, Jiuyo Capital is an equity investment firm. The company has three main business segments: investment management, FA services, and financial consulting.
Jiuyo Capital mainly invests in the field of AI technology, communication technology, new materials, advanced manufacturing, innovative drugs, and precision medicine.
Founded in Shenzhen in 2007, Share Capital is the earliest professional venture capital firm of limited partnership in China. Share Capital focuses on the early and mid-stage investment in health care and housing. So far, it has established 11 funds with AUM over 8 billion yuan.